Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells

Many breast cancer deaths result from tumors acquiring resistance to available therapies. Thus, new therapeutic agents are needed for targeting drug-resistant breast cancers. Drug-refractory breast cancers include HER2+ tumors that have acquired resistance to HER2-targeted antibodies and kinase inhi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Ferreira, Renan B., Wang, Mengxiong, Law, Mary E., Davis, Bradley J., Bartley, Ashton N., Higgins, Paul J., Kilberg, Michael S., Santostefano, Katherine E., Terada, Naohiro, Heldermon, Coy D., Castellano, Ronald K., Law, Brian K.
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2017
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5438706/
https://ncbi.nlm.nih.gov/pubmed/28423644
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.15952
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars